Intellia Therapeutics Names Muna Bhanji, R.Ph., to its Board of Directors
02. Mai 2022 16:01 ET
|
Intellia Therapeutics, Inc.
CAMBRIDGE, Mass., May 02, 2022 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading genome editing company focused on developing potentially curative therapeutics leveraging...
Intellia Therapeutics Presents Preclinical Data Demonstrating Advancements in its CRISPR-Engineered Allogeneic Platform at the 2022 Keystone Symposia’s Precision Genome Engineering Conference
02. Mai 2022 07:30 ET
|
Intellia Therapeutics, Inc.
Data highlight proprietary allogeneic cell engineering platform capable of creating immune-evading T cells and deployable for TCR-T and CAR-T cell therapyFindings support recent development candidate...
Intellia Therapeutics to Hold Conference Call to Discuss First Quarter 2022 Earnings and Company Updates
28. April 2022 07:30 ET
|
Intellia Therapeutics, Inc.
CAMBRIDGE, Mass., April 28, 2022 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage genome editing company focused on developing potentially curative...
Intellia Therapeutics Receives U.S. FDA Orphan Drug Designation for NTLA-5001 for the Treatment of Acute Myeloid Leukemia
09. März 2022 16:01 ET
|
Intellia Therapeutics, Inc.
CAMBRIDGE, Mass., March 09, 2022 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage genome editing company focused on developing potentially curative...
Intellia Therapeutics Announces First Patient Dosed in Phase 1/2a Clinical Trial of NTLA-5001 for the Treatment of Acute Myeloid Leukemia
01. März 2022 07:30 ET
|
Intellia Therapeutics, Inc.
NTLA-5001 is a novel investigational T cell receptor (TCR)-T cell therapy which leverages Intellia’s proprietary cell engineering platform NTLA-5001 targets Wilms’ Tumor 1 (WT1), an overexpressed...
Intellia and Regeneron Announce Updated Phase 1 Data Demonstrating a Single Dose of NTLA-2001, an Investigational CRISPR Therapy for Transthyretin (ATTR) Amyloidosis, Resulted in Rapid, Deep and Sustained Reduction in Disease-Causing Protein
28. Februar 2022 16:01 ET
|
Intellia Therapeutics, Inc.
Achieved 86% and 93% mean serum TTR reduction by day 28 at 0.7 mg/kg and 1.0 mg/kg doses, respectively, with dose-dependent reductions observed across all four dose levelsDurable serum TTR reductions...
Intellia Therapeutics Announces Fourth Quarter and Full-Year 2021 Financial Results and Highlights Recent Company Progress
24. Februar 2022 07:30 ET
|
Intellia Therapeutics, Inc.
On track to present additional interim data from dose-escalation portion of the ongoing Phase 1 study in patients with transthyretin (ATTR) amyloidosis with polyneuropathy on February 28, at 4:30 p.m....
Intellia Therapeutics Enters Lease Agreement to Build Manufacturing Facility for its CRISPR-based Therapies
23. Februar 2022 08:00 ET
|
Intellia Therapeutics, Inc.
State-of-the-art GMP manufacturing facility to support preclinical through commercial production of Intellia’s investigational therapiesNew facility in Waltham, Massachusetts expected to be...
Intellia Therapeutics Announces Two Upcoming Investor Events in February 2022
17. Februar 2022 07:30 ET
|
Intellia Therapeutics, Inc.
Fourth quarter and full-year 2021 financial results – February 24, at 8:00 a.m. ETUpdated interim clinical data from the ongoing Phase 1 study of NTLA-2001 for the treatment of transthyretin (ATTR)...
Intellia and ONK Therapeutics Announce Collaboration to Advance Allogeneic CRISPR-Edited NK Cell Therapies for the Treatment of Patients with Cancer
15. Februar 2022 07:30 ET
|
Intellia Therapeutics, Inc.
Collaboration combines Intellia’s genome editing platform with ONK’s optimized natural killer (NK) cell therapy platform Intellia grants ONK non-exclusive rights to its ex vivo genome editing and LNP...